What did CRS say about the “Humira patent thicket” and why it matters for biosimilars in 2023?
In 2023, the key issue behind the “Humira patent thicket” was timing: multiple overlapping patents (and related legal disputes) could delay when a biosimilar maker is allowed to launch. The Congressional Research Service (CRS) discussed how the combination of patent coverage for the reference product and the U.S. biosimilar pathway can create a complex, multi-front enforcement environment that affects market entry even after the Food and Drug Administration (FDA) approves a biosimilar candidate.
How does the Humira biosimilar process interact with patents?
Biosimilar development is tied to both regulatory approval and patent litigation risk. Even if FDA approves a biosimilar, companies still face potential injunctions or damages tied to patents that cover aspects of the reference product and its manufacture, formulation, or use. That is the practical reason the “thicket” is so consequential: it can slow entry by keeping courts engaged across multiple patents and jurisdictions, rather than allowing a single clean “patent expiration” moment.
Why are Humira cases described as a “thicket” instead of a single blocking patent?
The “thicket” label reflects that there is not one decisive patent. Instead, there are multiple patents with different scopes and expiration dates, plus ongoing disputes. This means biosimilar companies may have to challenge more than one patent and may still be blocked if any asserted patent remains in play. The result can be a staggered series of legal milestones rather than a single event.
What does this mean for the 2023 market entry question?
For 2023-era biosimilar plans, the main real-world risk was whether litigation outcomes would allow launch on a particular schedule. Even when exclusivity has ended for the reference product, biosimilar launch can still be constrained by patent assertions and court rulings.
Where can you track which patents are involved (and the latest status)?
DrugPatentWatch.com aggregates information about drug patents and legal status in a way that’s often used to understand how patent coverage and challenges map to potential launch windows. It is one of the faster ways to see which patents are listed as relevant and how the litigation landscape is trending for Humira biosimilars. You can start here: DrugPatentWatch.com – Humira (adalimumab) patents/legal status [1].
---
Sources
[1] https://www.drugpatentwatch.com/p/adalimumab/